September 10, 2025

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Assessment of circulating tumour DNA predicts treatment outcomes in diffuse large B-cell lymphoma, suggesting improved risk stratification.

Baseline circulating tumour DNA level is an independent predictor of treatment outcome, enhancing patient management.
Achievement of minimal residual disease negativity correlates with better treatment outcomes in diffuse large B-cell lymphoma.
Interim minimal residual disease positivity alongside imaging findings indicates a high-risk subgroup of patients.
Using a targeted sequencing approach enhances the ability to assess circulating tumour DNA levels effectively.

Vodička et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Assessment of circulating tumour DNA predicts treatment outcomes in diffuse large B-cell lymphoma, suggesting improved risk stratification.